ADC Landscape
ADC Therapeutics
CD19 · Diffuse large B-cell lymphoma
ApprovedAntibody–Drug Conjugates
Target
CD19
Payload
PBD dimer (SG3199)
Payload class
DNA-crosslinker (PBD)
Linker
Cleavable val-ala
Indication
Diffuse large B-cell lymphoma
Phase
Approved
Overview
Showcase for the ultra-potent PBD-dimer payload class. Higher potency, narrower window — the high-risk/high-reward end of payload chemistry.
Technology
ADC Therapeutics works in Antibody–Drug Conjugates — A guided missile: an antibody that flies a chemo warhead straight to the tumor.
Read the Antibody–Drug Conjugates brief →Related companies
Daiichi Sankyo
HER2
Gilead
TROP2
AstraZeneca / Daiichi
TROP2
Pfizer (Seagen)
CD30
Pfizer (Seagen)
Nectin-4
Pfizer (Seagen)
Tissue Factor
Company website / source ↗ Open the interactive map →
◢ Boom-cycle briefing
Get ahead of the next biotech boom.
New companies, stage changes, deal alerts and fresh tech briefs — one sharp email when the map moves.
Curated biotech intelligence, compiled for orientation — not investment advice. Company stages, deals and figures move fast; verify against ClinicalTrials.gov, company filings and primary sources before acting.